The present invention provides a metastin derivative having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action. Specifically, the present invention the metastin derivative (I), which is represented by formula: [wherein, Z1, Z3, Z5 and Z7 represent H or a C1-3 alkyl group; Z2, Z4, Z6 and Z8 represent H, O or S; R1 represents (1) H, or (2) a C1-8 alkyl group optionally substituted with a substituent selected from the group consisting of a carbamoyl group, a hydroxyl group and a aromatic cyclic group; R2 represents (1) H or (2) a cyclic or linear C1-10 alkyl group, or (3) a C1-10 alkyl group consisting of a cyclic alkyl group and a linear alkyl group; R3 represents a C1-8 alkyl group having a basic group, an aralkyl group having a basic group, a C1-4 alkyl group having a non-aromatic cyclic hydrocarbon group of carbon atoms not greater than 7 having a basic group, or a C1-4 alkyl group having a non-aromatic heterocyclic group of carbon atoms not greater than 7 having a basic group; R4 represents a C1-4 alkyl group, which may optionally be substituted with a substituent selected from the group consisting of a C6-12 aromatic hydrocarbon group, an aromatic heterocyclic group, a C8-14 aromatic fused-ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group, and a non-aromatic heterocyclic group having carbon atoms not greater than 7; X represents a group shown by formula: -NHCH(Q1)YQ2C(=Z9)- (wherein, Q1 represents a C1-4 alkyl group, which may optionally be substituted with a substituent selected from the group consisting of an aromatic hydrocarbon group, an aromatic heterocyclic group, a C8-14 aromatic fused-ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group having carbon atoms not greater than 7, and a non-aromatic heterocyclic group having carbon atoms not greater than 7; Q2 represents CH2, NH or O; Y represents -CONH-, -CSNH-, -CH2NH-, -NHCO-, -CH2O-, -CH2S- or -CH2CH2-; Z9 represents H, O or S); and P represents (1) H; (2) an optional amino acid residue continuously or discontinuously bound from the C-terminal end of the 1-48 amino acid sequence in the amino acid sequence represented by SEQ ID NO: 1; (3) a group represented by formula: J1-J2-C(J3)(Q3)Y1C(J4)(Q4)Y2C(J5)(Q5)Y3C(J6)(Q6)C(=Z10)-(wherein, J1 represents (a) H or (b) (i) a C1-15 acyl group, (ii) a C1-15 alkyl group, (iii) a carbamoyl group, (iv) a C1-15 alkylcarbamoyl group, (v) a C1-15 alkanoylcarbamoyl group, (vi) an aminocarbamoyl group, (vii) a C1-15 alkylaminocarbamoyl group, (viii) an oxycarbonyl group, (ix) a C1-15 alkoxylcarbonyl group, (x) a sulfonyl group, (xi) an amidino group, (xii) a C1-15 alkylamidino group, (xiii) a C1-15 acylamidino group, (xiv) a C1-15 alkylsulfonyl group, or (xv) a oxaryl group, which group may optionally be substituted with cyclic group; J2 represents NH, CH2, O or S; J3 through J6 represent H or a C1-3 alkyl group; Q3 through Q6 represent a C1-4 alkyl group, which may optionally be substituted with a substituent selected from the group consisting of a C6-12 aromatic hydrocarbon group, an aromatic heterocyclic group, a C8-14 aromatic fused-ring group, an aromatic fused heterocyclic group, a non-aromatic cyclic hydrocarbon group having carbon atoms not greater than 7, a non-aromatic heterocyclic group having carbon atoms not greater than 7, an amino group, a guanidino group, a hydroxyl group, a carboxyl group, a carbamoyl group, and a sulfhydryl group, or H; J3 and Q3, J4 and Q4, J5 and Q5 or J6 and Q6 may be combined together, or, J2 and Q3, Y1 and Q4, Y2 and Q5, or Y3 and Q6 may be combined together, to form a ring; Y1 through Y3 represent a group represented by formula: -CON(J13)-, -CSN(J13)-, -C(J14)N(J13)- or -N(J13)CO- (wherein J13 and J14 represent H or a C1-3 alkyl group); and Z10 represents H, O or S); (4) a group represented by formula: J1-J2-C(J7)(Q7)Y2C(J8)(Q8)Y3C(J9)(Q9)C(=Z10)- (wherein, J1 and J2 have the same significance as described above; J7 through J9 have the same significance as J3; Q7 through Q9 have the same significance as Q3; Y2 and Y3 have the same significance as described above; Z10 has the same significance as described above; J7 and Q7, J8 and Q8 or J9 and Q9 may be combined together, or, J2 and Q7, Y2 and Q8 or Y3 and Q9 may be combined together, to form a ring); (5) a group represented by formula: J1-J2-C(J10)(Q10)Y3C(J11)(Q11)C(=Z10)- (wherein, J1 and J2 have the same significance as described above represents; J10 and J11 have the same significance as J3; Q10 and Q11 have the same significance as Q3; Y3 has the same significance as described above; Z10 has the same significance as described above; and J10 and Q10 or J11 and Q11 may be combined together, or J2 and Q10 or Y3 and Q11 may be combined together, to form a ring); (6) a group represented by formula: J1-J2-C(J12)(Q12)C(=Z10)- (wherein, J1 and J2 have the same significance as described above; J12 has the same significance as J3; Q12 has the same significance as Q3; Z10 has the same significance as described above; and J12 and Q12 may be combined together, or J2 and Q12 may be combined together, to form a ring); or (7) a group represented by formula: J1- (wherein, J1 has the same significance as described above)], or a salt thereof.